Sign inCreate account

Report workspace

Add to folder
NCT06392126ACTIVE_NOT_RECRUITINGanonymous

An Open-label Study of an Experimental Antisense Oligonucleotide Treatment for a Single Participant With Amyotrophic Lateral Sclerosis (ALS) Due to a Pathogenic Variant in CHCHD10

Sponsor

Source record

n-Lorem Foundation

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

nL-CHCHD-001

Indication / condition

AI-normalized

Amyotrophic Lateral Sclerosis

Intervention

Source record

nL-CHCHD-001

Source & freshness

Source record

NCT ID

NCT06392126

Original source

ClinicalTrials.gov

Source last updated

Aug 05, 2025

Ingested at

Jun 17, 2026

Internal sync

Jun 17, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06392126

Title

An Open-label Study of an Experimental Antisense Oligonucleotide Treatment for a Single Participant With Amyotrophic Lateral Sclerosis (ALS) Due to a Pathogenic Variant in CHCHD10

Sponsor

n-Lorem Foundation

Status

ACTIVE_NOT_RECRUITING

Phase

PHASE1

Condition raw

Amyotrophic Lateral Sclerosis

Condition normalized

Amyotrophic Lateral Sclerosis

Modality raw

small molecule

Modality normalized

small molecule

Target raw

nL-CHCHD-001

Target normalized

nL-CHCHD-001

Interventions

nL-CHCHD-001

Public preview

Source record

This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

An Open-label Study of an Experimental Antisense Oligonucleotide Treatment for a Single Participant With Amyotrophic Lateral Sclerosis (ALS) Due to a Pathogenic Variant in CHCHD10

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 17, 2026

NCT ID

NCT06392126

Status

ACTIVE_NOT_RECRUITING

Phase

PHASE1

Sponsor

n-Lorem Foundation

Executive brief

Investment-Ready Snapshot

This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedAug 05, 2025
Internal syncJun 17, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06392126

Indication

Amyotrophic Lateral Sclerosis

Modality

small molecule

Target

nL-CHCHD-001

Intervention

nL-CHCHD-001

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.